Provident Financial Services, Inc. PFS
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- +16.15%
- 1 year
- +24.07%
- Open
- 23.09
- Prev close
- 23.17
- Mkt cap
- 2.99B
- Vol
- 955.93K
- Avg vol
- 835.98K
- EPS
- 2.40
- P/E
- 9.56
- Div yield
- 4.14%
More statistics
- Low
- 22.87
- High
- 23.31
- Forward P/E
- 8.87
- Beta
- 0.82
- Short ratio
- 6.45
- Inst. own
- 76.94%
- Dividend
- 0.96
- Ex-div date
- Aug 13, 2026
- Earnings
- Jan 26, 2027
- 50-d avg
- 22.89
- 200-d avg
- 22.62
- 1y target
- 27.83
5D chart
Events in this range
- Oct 28, 2026Earnings: 0.65; estimate 0.612; surprise 6.21%
Signals (86)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:55 AM | 4 days ago |
| RSI: Oversold | Oct 28, 10:25 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
1 day ago marketbeat.com
Provident Financial Services Q3 Earnings Call Highlights
Provident Financial Services NYSE: PFS reported third-quarter 2026 core net income of $84 million, or $0.65 per diluted share, as record operating revenue and continued loan and deposit growth…
2 days ago globenewswire.com
Provident Financial Services, Inc. Declares Quarterly Cash Dividend
ISELIN, NJ, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) Board of Directors declared a quarterly cash dividend of $0.24 per common share payable on…
2 days ago seekingalpha.com
Provident Financial Services, Inc. (PFS) Q3 2026 Earnings Call Transcript
Provident Financial Services, Inc. ( PFS ) Q3 2026 Earnings Call October 29, 2026 10:00 AM EDT Company Participants Michael Perito - Senior VP & Investor Relations Officer Anthony Labozzetta -…
3 days ago benzinga.com
Provident Finl Servs Q3 2026 Earnings Call Transcript
Provident Finl Servs (NYSE:PFS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
3 days ago zacks.com
Provident Financial (PFS) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Provident Financial (PFS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
3 days ago zacks.com
Provident Financial (PFS) Lags Q3 Earnings Estimates
Provident Financial (PFS) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.55 per share a year ago.
3 days ago globenewswire.com
Provident Financial Services, Inc. Reports Third Quarter Earnings
ISELIN, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE: PFS) (the “Company”) reported net income of $69.2 million, or $0.53 per basic and diluted share for the three…
5 days ago seekingalpha.com
Provident Financial Services Can Still Move Up From Here
Provident Financial Services, Inc. remains a Buy due to robust asset quality, attractive valuation, and ongoing earnings growth. PFS's deposit base has grown, with high-cost brokered deposits at only…
6 days ago zacks.com
Why Provident Financial (PFS) is Poised to Beat Earnings Estimates Again
Provident Financial (PFS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
1 week ago gurufocus.com
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
1 week ago gurufocus.com
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Positive results from the SAFFRON Phase III trial showed TAGRISSOÂ (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meani
1 week ago gurufocus.com
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
1 week ago gurufocus.com
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod
1 week ago gurufocus.com
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPR Newswire
1 week ago gurufocus.com
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
1 week ago gurufocus.com
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
1 week ago gurufocus.com
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C
1 week ago gurufocus.com
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
1 week ago marketbeat.com
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective Therapeutics NYSEAMERICAN: CATX presented updated clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2026, reporting tumor responses, an…
1 week ago gurufocus.com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim an
1 week ago zacks.com
Provident Financial (PFS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Provident Financial (PFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
3 months ago benzinga.com
Keefe, Bruyette & Woods Reiterates Outperform on Provident Finl Servs, Raises Price Target to $28
Keefe, Bruyette & Woods analyst Timothy Switzer reiterates Provident Finl Servs (NYSE:PFS) with a Outperform and raises the price target from $26 to $28.
-
3 months ago benzinga.com
Piper Sandler Reiterates Overweight on Provident Finl Servs, Raises Price Target to $29
Piper Sandler analyst Manuel Navas reiterates Provident Finl Servs (NYSE:PFS) with a Overweight and raises the price target from $26 to $29.
-
3 months ago benzinga.com
Provident Finl Servs Q2 EPS $0.60 Beats $0.56 Estimate, Sales $202.680M Miss $206.371M Estimate
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.56 by 7.14 percent. This is a 9.09 percent increase over earnings of…
-
4 months ago benzinga.com
Raymond James Maintains Strong Buy on Provident Finl Servs, Raises Price Target to $27
Raymond James analyst Steve Moss maintains Provident Finl Servs (NYSE:PFS) with a Strong Buy and raises the price target from $25 to $27.
-
4 months ago benzinga.com
Provident Financial Services Appoints Adriano Duarte CFO, Effective July 1
Provident Bank, a leading New Jersey-based financial institution, announced today the appointment of Adriano Duarte to Executive Vice President and Chief Financial Officer of Provident Bank and…
-
4 months ago benzinga.com
Stephens & Co. Initiates Coverage On Provident Finl Servs with Equal-Weight Rating, Announces Price Target of $24
Stephens & Co. analyst Matt Breese initiates coverage on Provident Finl Servs (NYSE:PFS) with a Equal-Weight rating and announces Price Target of $24.
-
6 months ago benzinga.com
Keefe, Bruyette & Woods Maintains Outperform on Provident Finl Servs, Raises Price Target to $26
Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) with a Outperform and raises the price target from $25 to $26.
6 months ago benzinga.com
Full Transcript: Provident Finl Servs Q1 2026 Earnings Call
Full Transcript: Provident Finl Servs Q1 2026 Earnings Call
-
6 months ago benzinga.com
Provident Finl Servs Q1 EPS $0.61 Beats $0.55 Estimate, Sales $225.196M Beat $208.384M Estimate
Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.55 by 10.91 percent. This is a 24.49 percent increase over earnings of…
6 months ago benzinga.com
Earnings Scheduled For April 29, 2026
Earnings Scheduled For April 29, 2026
-
9 months ago benzinga.com
Earnings Scheduled For January 27, 2026
Earnings Scheduled For January 27, 2026
9 months ago benzinga.com
Earnings Volatility Watch: These 10 Stocks Could Swing 30% Or More This Week
Options markets are pricing in post-earnings swings of up to 50% this week, with regional banks in focus and the Fed decision set to amplify volatility.
1 year ago benzinga.com
Earnings Scheduled For October 29, 2025
Earnings Scheduled For October 29, 2025
-
1 year ago benzinga.com
Earnings Scheduled For January 28, 2025
Earnings Scheduled For January 28, 2025
-
2 years ago benzinga.com
Earnings Scheduled For April 18, 2024
Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ:ADXN) is estimated to report earnings for its fourth quarter.
-
2 years ago benzinga.com
Real Estate, Regional Bank Stocks Tank, Energy Cushions The Blow: March Inflation Rates Shake Up Sectors
Inflation unexpectedly surges, shattering hopes for Fed rate cuts & sending stocks down. Core inflation also exceeded expectations. No sector escapes losses, with real estate hit hardest.
-
2 years ago benzinga.com
Earnings Scheduled For January 25, 2024
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is projected to report quarterly earnings at $0.15 per share on revenue of $7.05 billion.
-
2 years ago benzinga.com
Exceeding Expectations: German American Bancorp Achieves Strong Performance and Rewards Investors
Exceeding Expectations: German American Bancorp Achieves Strong Performance and Rewards Investors
-
3 years ago benzinga.com
Earnings Scheduled For October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
-
3 years ago benzinga.com
Earnings Scheduled For July 27, 2023
Companies Reporting Before The Bell • SES AI (NYSE:SES) is projected to report quarterly earnings at $0.11 per share on revenue of $337.60 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 498 companies reached new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 345 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 286 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 141 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 127 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 220 stocks hit new 52-week lows.